STOCK TITAN

FibroGen to Report First Quarter 2024 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

FibroGen, Inc. (NASDAQ: FGEN) will report its first quarter 2024 financial results on May 6 after the market close. The company will hold a conference call to discuss its financial and corporate performance.

Interested parties can access the live webcast on the company's website. Dial-in details are available for phone participants. A webcast replay will be available for a time.

FibroGen, Inc. (NASDAQ: FGEN) comunicherà i risultati finanziari del primo trimestre del 2024 il 6 maggio dopo la chiusura del mercato. La società terrà una conferenza telefonica per discutere delle sue prestazioni finanziarie e aziendali. Le parti interessate possono accedere alla trasmissione web in diretta sul sito web della compagnia. I dettagli per la partecipazione telefonica sono disponibili. Una replica della webcast sarà disponibile per un certo periodo.
FibroGen, Inc. (NASDAQ: FGEN) informará sobre sus resultados financieros del primer trimestre de 2024 el 6 de mayo después del cierre del mercado. La empresa realizará una conferencia telefónica para discutir su rendimiento financiero y corporativo. Las partes interesadas podrán acceder a la transmisión en vivo en el sitio web de la compañía. Están disponibles los detalles para participar por teléfono. Se ofrecerá una repetición de la webcast por un tiempo determinado.
FibroGen, Inc. (NASDAQ: FGEN)는 2024년 첫 번째 분기 재무 결과를 5월 6일 시장 마감 후 보고할 예정입니다. 회사는 재무 및 기업 성과에 대해 논의하기 위해 컨퍼런스 콜을 개최할 것입니다. 관심 있는 당사자들은 회사 웹사이트에서 실시간 웹캐스트를 접속할 수 있습니다. 전화 참여자를 위한 접속 정보도 제공됩니다. 웹캐스트 리플레이는 일정 기간 동안 제공될 것입니다.
FibroGen, Inc. (NASDAQ: FGEN) publiera ses résultats financiers pour le premier trimestre 2024 le 6 mai après la clôture du marché. La société organisera une conférence téléphonique pour discuter de ses performances financières et corporatives. Les parties intéressées pourront accéder à la webdiffusion en direct sur le site web de l'entreprise. Les détails pour participer par téléphone sont disponibles. Une rediffusion de la webcast sera disponible pendant une certaine période.
FibroGen, Inc. (NASDAQ: FGEN) wird am 6. Mai nach Börsenschluss seine Finanzergebnisse für das erste Quartal 2024 berichten. Das Unternehmen wird eine Telefonkonferenz abhalten, um seine finanzielle und unternehmerische Leistung zu diskutieren. Interessierte Parteien können den Live-Webcast auf der Website des Unternehmens verfolgen. Einwahldetails sind für Telefon-Teilnehmer verfügbar. Eine Wiedergabe des Webcasts wird für eine bestimmte Zeit verfügbar sein.
Positive
  • None.
Negative
  • None.

SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial in to the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).

About FibroGen  
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, a fully human anti-CTGF monoclonal antibody, is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.

Contacts: FibroGen, Inc.

Investors:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
InvestorRelations@fibrogen.com 

Media:
Meichiel Keenan
Director, Investor Relations and Corporate Communications
media@fibrogen.com 


FAQ

When will FibroGen report its first quarter 2024 financial results?

FibroGen will report its first quarter 2024 financial results on May 6 after the market close.

How can interested parties access the conference call?

Interested parties can access the live webcast on the company's website or use dial-in details provided for phone participants.

Is there a webcast replay available?

Yes, a webcast replay will be available for a time following the conference call.

FibroGen, Inc.

NASDAQ:FGEN

FGEN Rankings

FGEN Latest News

FGEN Stock Data

112.41M
90.61M
0.87%
62%
7.42%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO